111, Inc.
YI · Price history
Price at last available close
$2.98
−$0.45 (-13.12%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About 111, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks.
How they make money
111, Inc. operates a tech-enabled healthcare platform in China that connects pharmaceutical companies with pharmacies and patients. The company generates revenue primarily through the sale of pharmaceutical products and health supplements, while also providing digital supply chain, marketing, and data services to upstream pharmaceutical manufacturers.
Products & services
The company provides an integrated online and offline platform offering pharmaceutical distribution, supply chain management, digital marketing, customer analytics, and patient education services.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company's business is highly fragmented with no single customer accounting for a significant portion of total net revenues as of the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Pharmaceutical Manufacturers — Various pharmaceutical manufacturers that supply medical products for distribution through the company's platform.Source
Competitors
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
26
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
30
Poor
Financial Strength
38
Business Quality / Moat
14
Management
73
Growth Quality
0
Risk / Durability
7
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
15
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
19/100
Building Historical Record
Model Score 19/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •M&A headline · Sep 17, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for YI
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving YI's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is YI's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Does YI's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for YI to reach sustainable profitability?
- •What future growth or profitability would be needed to justify YI's current valuation?
Essential Investment Snapshot
Wall Street Score
26
Opportunity Score
15
Market Cap
$26.2M
P/E Ratio
-1.7
EPS
$-1.78
52-Week High
$11.17
52-Week Low
$2.48
Beta
0.67
Shares Outstanding
8.7M
Total Revenue
$1.56B
Total Debt
$42.2M
Dividend
No current dividend
Liquidation Value / Share
$2.75
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for YI
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-0.3x). Earnings may be strained to cover interest expense.
M&A headline · Sep 17, 2026
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
PRNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on YI.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Extensive digital supply chain network.
- +Data-driven marketing and analytics capabilities.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Distribution industry.
- −Regulatory changes in the Chinese healthcare and e-commerce sectors.
- −Intense competition in the online pharmaceutical retail market.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
26
Oct 1, 2026
Change
Unchanged
Current Score
26
Oct 29, 2026
Category Changes
YI score was unchanged.
Projected Score
Projected Score
23
Projected Change
-3.4 points
Preliminary comparable-period financial changes suggest decline of approximately 3.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$2.98
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.56B | $1.83B | $2.16B | $2.24B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.47B | $1.72B | $2.03B | $2.11B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $89.6M | $105.3M | $124.1M | $127.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $56.4M | $98.0M | $57.6M | $100.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $97.2M | $106.8M | $123.8M | $179.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$4.3M | $271K | $3.7M | -$46.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$7.5M | -$1.5M | $316K | -$52.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $5.2M | $5.2M | $4.2M | $3.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$9.9M | -$3.3M | -$3.1M | -$52.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $2K | $14K | $38K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$14.2M | -$2.5M | -$9.7M | -$58.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.78 | $-1.11 | $-1.13 | $-6.97 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 8.82M | 8.70M | 8.62M | 8.43M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 8.82M | 8.70M | 8.62M | 8.43M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$344.3M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.66
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+32.4%
Cash Change
-28.2%
Margin Change
-1.1 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included EPS growth. Pressure indicators included revenue growth, cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 28.3%. EPS increased 96.4%. Cash declined 28.2%. Total debt increased 32.4%. Net income margin declined by 1.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DistributionNews
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
111, Inc. Announces Establishment of the Special Committee
111, Inc. Announces Establishment of the Special Committee
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
Rumor Mill · YI
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial